VBIV (VBI Vaccines, Inc.) שווי החברה בספרים

Amidst fierce competition in the immuno-oncology segment and a capital deficit, VBI Vaccines Inc. (VBIV) is forced to seek strategic partners. This chart on GURU.Markets illustrates the price action of the asset, which is currently valued at -0.01. The business relies on unique VLP technology, creating a powerful defensive barrier in the form of a hepatitis B vaccine. Revenue is generated through drug sales and grant payments.

Stable revenue from the commercialization of hepatitis B vaccines and patent protection provide VBI Vaccines Inc. (VBIV) with a solid foundation for asset growth. By analyzing capital dynamics via the balance sheet on GURU.Markets, an investor can identify the net asset value minus all liabilities, enabling a real-time assessment of the issuer's intrinsic value and minimizing risks during periods of high market volatility.